Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.
Hartog H, Horlings HM, van der Vegt B, Kreike B, Ajouaou A, van de Vijver MJ, Marike Boezen H, de Bock GH, van der Graaf WT, Wesseling J. Hartog H, et al. Among authors: van der graaf wt, van de vijver mj, de bock gh, van der vegt b. Breast Cancer Res Treat. 2011 Oct;129(3):725-36. doi: 10.1007/s10549-010-1256-6. Epub 2010 Nov 24. Breast Cancer Res Treat. 2011. PMID: 21107683
Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy.
van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Velde CJ, van de Vijver MJ. van Slooten HJ, et al. Among authors: van dierendonck jh, van de vijver mj, van de velde cj. Br J Cancer. 1996 Jul;74(1):78-85. doi: 10.1038/bjc.1996.319. Br J Cancer. 1996. PMID: 8679463 Free PMC article. Clinical Trial.
Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression.
Elkhuizen PH, Voogd AC, van den Broek LC, Tan IT, van Houwelingen HC, Leer JW, van de Vijver MJ. Elkhuizen PH, et al. Among authors: van houwelingen hc, van de vijver mj, van den broek lc. Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):73-83. doi: 10.1016/s0360-3016(99)00158-3. Int J Radiat Oncol Biol Phys. 1999. PMID: 10477009 Clinical Trial.
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.
Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ. Bijker N, et al. Among authors: van de vijver mj, de mascarel i. J Clin Oncol. 2001 Apr 15;19(8):2263-71. doi: 10.1200/JCO.2001.19.8.2263. J Clin Oncol. 2001. PMID: 11304780 Clinical Trial.
A gene-expression signature as a predictor of survival in breast cancer.
van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. van de Vijver MJ, et al. Among authors: van t veer lj, van der velde t. N Engl J Med. 2002 Dec 19;347(25):1999-2009. doi: 10.1056/NEJMoa021967. N Engl J Med. 2002. PMID: 12490681 Free article.
312 results